Announcements Announcements 2023 Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 Continue Reading
Announcements Announcements 2023 Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001 Continue Reading
Announcements Announcements 2022 Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy Continue Reading
Announcements Announcements 2022 Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022 Continue Reading
Announcements Announcements 2021 Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies Continue Reading
Announcements Announcements 2021 Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers Continue Reading
